A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Patients With Relapsed or Refractory Hairy Cell Leukemia (HCL).
Phase of Trial: Phase I
Latest Information Update: 06 Dec 2017
At a glance
- Drugs Moxetumomab pasudotox (Primary)
- Indications Hairy cell leukaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors MedImmune
- 06 Dec 2017 Data from this trial will be presented at the 59th 2017 American Society of Hematology (ASH) Annual Meeting & Exhibition, according to an AstraZeneca media release.
- 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
- 09 Jul 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History